Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and failure to disclose significant operational issues that have negatively impacted the company's financial performance [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and operational challenges, particularly in their High-Value Products portfolio [4]. - Specific issues highlighted include the operational inefficiencies of the SmartDose device, which was expected to be a high-margin growth product but instead diluted profit margins [4]. - The allegations also mention the risk of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers, due to these margin pressures [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to contract manufacturing headwinds and the loss of two major customers [5]. - Following this announcement, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on the same day [5]. Group 3: Legal Proceedings - Investors who purchased securities in West between February 16, 2023, and February 12, 2025, are encouraged to discuss their legal rights and options, with a deadline of July 7, 2025, to seek the role of lead plaintiff in the federal securities class action [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [6].

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical Services made false statements regarding customer demand and attributed challenges to temporary COVID-related product destocking, while in reality, the company was facing significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially false or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified time frame have until July 7, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members, and there is no obligation to participate [4]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

West Pharmaceutical Services, Inc. Eric M. Green President, CEO and Chair of the Board William Blair 45th Annual Growth Stock Conference June 5, 2025 Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product develop ...

Core Viewpoint - West Pharmaceutical Services, Inc. is facing a federal securities class action due to disappointing revenue and earnings forecasts, attributed to operational challenges and customer losses during the Class Period from February 16, 2023, to February 12, 2025 [1][3]. Group 1: Financial Performance and Forecasts - On February 13, 2025, West issued weak revenue and earnings forecasts for 2025, citing challenges including the loss of two major continuous glucose monitoring (CGM) customers transitioning to in-house manufacturing [3]. - The company's share price dropped by approximately 38%, from $322.28 on February 12, 2025, to $199.11 on February 13, 2025, following the announcement [3]. Group 2: Allegations in the Class Action - The complaint alleges that West failed to disclose significant destocking issues in its high-margin HVP portfolio, contrary to claims of strong visibility into customer demand [4]. - It is claimed that the SmartDose device, positioned as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [4]. - The margin pressures faced by West raised concerns about potential costly restructuring activities, including exiting CGM contracts with long-standing customers [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 7, 2025 [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against West Pharmaceutical - The lawsuit alleges that West Pharmaceutical made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5]. - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements about strong customer demand [5]. - The operational inefficiencies of the SmartDose device reportedly diluted profit margins, leading to potential restructuring activities and exit from key contracts [5].

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud during the specified period [2]. - The complaint claims that West Pharmaceutical Services made false statements regarding customer demand and operational challenges, particularly in its high-margin HVP portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [3]. Group 2: Financial Implications - The margin pressures faced by the company could lead to costly restructuring activities, including exiting contracts related to continuous glucose monitoring with long-standing customers [3]. - The lawsuit contends that the positive statements made by the company regarding its business and prospects were materially false or misleading [3]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 4: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Summary of West Pharmaceutical Services (WST) FY Conference Company Overview - **Company**: West Pharmaceutical Services (WST) - **Industry**: Pharmaceutical packaging and drug delivery systems - **Conference Date**: June 05, 2025 Key Points Investment Thesis - **Sustainable Growth**: The company emphasizes a strong platform driving sustainable growth over the years, focusing on primary containment and drug delivery devices [4][5] - **Global Reach**: West serves the global pharmaceutical market, supporting both small biotech firms and large pharmaceutical companies [5] - **High Production Volume**: The company manufactures over 41 billion components annually, impacting over 100 million patients daily [6] Product Portfolio - **Diverse Offerings**: The portfolio includes a significant focus on biologics and biosimilars, with approximately 40% of the business supporting these areas [8] - **High Value Products (HVP)**: HVPs account for about 60% of revenues and over 75% of growth profits, indicating a strong market demand [10] - **Long Product Life Cycle**: West participates in the lifecycle of drug molecules, often for decades, adapting to regulatory changes [12] Market Trends - **Injectable Medicines Growth**: The injectable medicine market is projected to grow, with West positioned to benefit from trends such as GLP-1s and hospital-to-home transitions [14][15] - **Market Size**: The injectable medicine and delivery devices market is estimated at $13 billion, growing at mid-single digits [15] Competitive Advantages - **Recurring Revenues**: Long-term partnerships with customers ensure stable revenue streams as they launch new drug molecules [16] - **Technological Integration**: Collaborations with partners enhance product development and manufacturing processes [17] - **Regulatory Expertise**: West's deep understanding of regulatory requirements positions it well to support customers in compliance [19] - **Infrastructure Investment**: Significant investments in high-value product facilities enhance production capabilities [20] Growth Drivers - **Biologics and Annex One**: The rise in biologics approvals and compliance with Annex One regulations are key growth areas [21][22] - **GLP-1 Market**: The company anticipates that GLP-1s will constitute about 40% of its contract manufacturing business by 2025 [28] - **Capital Investments**: Over the last five years, West has invested approximately $1 billion in facilities to support growth [32] Financial Outlook - **Operating Margin Growth**: The company expects to achieve over 100 basis points of operating margin growth annually under normalized market conditions [13] - **Long-term Financial Goals**: West aims for a long-term organic growth rate of 7% to 9% [38] Challenges and Mitigation - **Tariff Impacts**: The company faces a gross headwind of $20 to $25 million due to tariffs but is implementing strategies to mitigate these impacts [37][38] Future Innovations - **Integrated Systems**: West is developing integrated systems, including fully characterized prefilled syringes, expected to launch in early 2026 [35] - **Cost Management**: The company is focused on improving margins through automation and cost reduction in its drug delivery devices segment [55] Conclusion - **Market Leadership**: West is positioned as a market leader in elastomers and components, with a robust platform for future growth in the injectable medicines sector [39][40] - **Commitment to Patient Health**: The company emphasizes its role in enhancing patient health through innovative solutions and strong customer partnerships [41]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In West To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - West Pharmaceutical Services, Inc. is facing a class action lawsuit due to significant stock price decline following disappointing revenue and earnings forecasts, attributed to operational challenges and customer losses [2][3]. Group 1: Company Performance - On February 13, 2025, West issued disappointing revenue and earnings forecasts for 2025, citing Contract Manufacturing headwinds and the loss of two major continuous glucose monitoring customers [2]. - The company's SmartDose wearable injector devices are expected to be "margin dilutive" in 2025, prompting the need for steps to improve its economics [2]. - Following the announcement, West's stock price fell by $123.17, or 38.2%, closing at $199.11 per share [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that West made materially false and misleading statements throughout the class period, failing to disclose significant operational issues [3]. - Specific allegations include ongoing destocking across West's high-margin HVP portfolio and operational inefficiencies related to the SmartDose device, which was expected to be a high-margin growth product [3]. - The lawsuit claims that these margin pressures could lead to costly restructuring activities, including exiting contracts with long-standing customers in the continuous glucose monitoring sector [3].

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...